by tempo | Dec 11, 2020 | Industry News
Thirty (30) years ago, exosomes were first described as extracellular vesicles (References 1 and 5). Extracellular vesicles (EVs) are cell derived membrane structures. They are secreted as a result of fusions between intracellular endosomes and the plasma membrane. ...
by tempo | Jul 8, 2020 | Cell Culture Techniques
Genetically encoded biosensors have become popular and powerful LIVE-cell reporters in recent years (see reference here). These biosensors can be incorporated into a variety of human inducible pluripotent stem cells (iPSCs) and iPSC-derived cell types (such as...
by tempo | Aug 7, 2019 | Disease Models
Cardiomyocytes are cardiac muscle cells. They are terminally differentiated and facilitate contractile forces (“beatings”) of the heart. Grown in vitro as a monolayer sheath, cardiomyocytes are connected by gap junction proteins that help synchronize...
by Angela L. Huang | Apr 10, 2019 | News
SAN FRANCISCO, CA —Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived products and affiliated cell-based services in the following categories:...
by Karen O'Hanlon Cohrt | Mar 22, 2019 | Disease Models
Welcome back to our cell of the month series. This time we’re talking about CD34+ cells, a type of undifferentiated multipotent hematopoetic stem cell (HSC) with the potential to differentiate into almost any other blood cell type under specific conditions. As stem...